Literature DB >> 2157399

Preparation of a detailed restriction map of the avian leukosis virus MAV-2(O).

R E Aurigemma1, M C Simon, W S Hayward, R E Smith.   

Abstract

Unintegrated MAV-2(O) DNA was isolated from infected chicken embryo fibroblasts and inserted into the lambda bacteriophage vector lambda gtWES lambda B. Three x 10(6) bacteriophage plaques were screened, yielding a total of seven clones, six of which contained DNA representing the complete MAV-2(O) genome. Viral DNA was isolated from four of the clones and was used to transfect chicken embryo fibroblasts. All four clones produced virus as monitored by reverse transcriptase assay. When the four cloned viruses were inoculated into 10-day-old embryos, all hatched chickens developed osteopetrosis. One clone, lambda 9, induced osteopetrosis at a rate of onset and severity identical to that induced by the MAV-2(O) parental stock. This clone was selected for further study. To facilitate restriction mapping, the viral DNA from lambda 9 was subcloned into plasmid vector pUC 12 to construct a plasmid called p9. Cleavage of p9 DNA with single and multiple restriction endonucleases and hybridization with gene-specific probes identified the restriction fragments obtained. A comprehensive restriction map of cloned MAV-2(O) was generated and is compared with published maps and sequences of other avian retroviruses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157399

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  2 in total

1.  The noncoding and surface envelope coding sequences of myeloblastosis-associated virus are respectively responsible for nephroblastoma development and renal hyperplasia.

Authors:  V Joliot; C Khelifi; M Wyers; G Dambrine; F Lasserre; P Lemercier; B Perbal
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

2.  Sequences from myeloblastosis-associated virus MAV-2(O) and UR2AV involved in the formation of plaques and the induction of osteopetrosis, anemia, and ataxia.

Authors:  R E Aurigemma; J L Torgersen; R E Smith
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.